IRCT20200421047153N1已完成3 期
A Community Trial to examine the effect of hydroxychloroquine prophylaxis in preventing the sever forms of Covid-19 in asymptomatic people
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 1,000
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 65 years（—）
- 性别
- All
入选标准
- •18-65 years old
- •No symptoms of corona and no positive corona test
- •The desire to participate in the study
- •No symptoms of disease at the time of admission
- •No positive test
排除标准
- •History of allergy to hydroxychloroquine
- •Contraindications for drug use include previous history of retinopathy or G6PD, LONG QT SYNDROME, porphyry
- •Positive HIV patients
- •Patients with autoimmune diseases (lupus-rheumatoid arthritis)
- •Using medications with contraindication to use hydroxychloroquine
研究者
相似试验
已完成
2 期
Hydroxychloroquine in prevention of sever forms of COVID-19 in healthcare workersIRCT20200424047184N1Islamic Azad University400
招募中
3 期
Investigating the efficacy and safety of Hydroxychloroquine nasal spray in controlling the symptoms of patients with COVID-19IRCT20080901001165N51Sina Darou Laboratories Company80
招募中
不适用
Open label trial for efficacy and safety of Hydroxychloroquine for systemic lupus erythematosusJPRN-UMIN000012478Department of Internal Medicine, Teikyo University School of Medicine10
尚未招募
不适用
International study in multiple centers studying the effect of hydroxy-urea and temozolomide chemotherapy in patients with a recurrent malignant brain tumor (Glioblastoma)Brain tumor, glioma, glioblastoma, recurrent glioblastoma, glioblastoma multiformeHersentumor, glioom, glioblastoom, recidief glioblastoom, glioblastoma multiformeNL-OMON20720VU University Medical Center35
已完成
不适用
International Multicenter Phase I trial of Hydroxyurea in Combination with Dose-Intense Temozolomide in Recurrent Glioblastoma.High grade glioma10029211brain tumorNL-OMON50467Vrije Universiteit Medisch Centrum49